CNTN-1 Enhances Chemoresistance in Human Lung Adenocarcinoma Through Induction of Epithelial-Mesenchymal Transition by Targeting the PI3K/Akt Pathway

被引:28
|
作者
Zhang, Ruijie [1 ]
Sun, Shenghua [1 ]
Ji, Fuyun [2 ]
Liu, Chun [1 ]
Lin, Hua [1 ]
Xie, Lihua [1 ]
Yang, Honghui [1 ]
Tang, Wenxiang [1 ]
Zhou, Yan [1 ]
Xu, Jianping [3 ]
Li, Pei [4 ,5 ]
机构
[1] Cent S Univ, Xiangya Hosp 3, Dept Resp Med, Changsha, Hunan, Peoples R China
[2] Third Mil Med Univ, Xinqiao Hosp, Inst Human Resp Dis, Chongqing, Peoples R China
[3] Third Mil Med Univ, Xinqiao Hosp, Dept Pathol, Chongqing, Peoples R China
[4] 89 Hosp PLA, Dept Orthoped Surg, Weifang, Shandong, Peoples R China
[5] Thrid Mil Med Univ, Dept Orthoped Surg, Southwest Hosp, Chongqing, Peoples R China
基金
中国国家自然科学基金;
关键词
CNTN-1; EMT; Chemoresistance; PI3K/Akt; NSCLC; LYMPH-NODE METASTASIS; OVARIAN-CANCER; CONTACTIN; CISPLATIN RESISTANCE; THERAPEUTIC TARGET; THYROID-CANCER; BREAST-CANCER; PROMOTES; CELLS; EXPRESSION;
D O I
10.1159/000480473
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Background/Aims:Chemoresistance has been a major obstacle to the effective treatment of lung cancer. Previously, we found that contactin-1 (CNTN-1) is related to cisplatin resistance in lung adenocarcinoma. Here, we aimed to investigate the underlying mechanism behind the role of CNTN-1 in cisplatin resistance in lung adenocarcinoma. Methods:EMT-associated phenotypes, including alterations in cellular morphology and marker (E-cadherin, N-cadherin and Vimentin) expression, were compared between A549 cells and A549/DDP cells (a cisplatin-resistant cell line of lung adenocarcinoma with abnormal CNTN-1 expression) by using real-time time PCR and Western blotting. Other methods, including CNTN-1 overexpression in A549 cells and CNTN-1 knockdown in A549/DDP cells, were also used to investigate the role of CNTN-1 in mediating the EMT phenotype and thr resulting cisplatin resistance and malignant progression of cancer cells in vitro and in vivo. Results: A549/DDP cells exhibited an EMT phenotype and aggravated malignant behaviors. CNTN-1 knockdown in A549/DDP cells partly reversed the EMT phenotype, increased drug sensitivity, and attenuated the malignant progression whereas CNTN-1 overexpression in A549 cells resulted in the opposite trend. Furthermore, the PI3K/Akt pathway was involved in the effects of CNTN-1 on EMT progression in A549/DDP cells, verified by the xenograft mouse model. Conclusion: CNTN-1 promotes cisplatin resistance in human cisplatin-resistant lung adenocarcinoma through inducing the EMT process by activating the PI3K/Akt signaling pathway. CNTN-1 may be a potential therapeutic target to reverse chemoresistance in cisplatin-resistant lung adenocarcinoma. (C) 2017 The Author(s). Published by S. Karger AG, Basel
引用
收藏
页码:465 / 480
页数:16
相关论文
共 50 条
  • [21] HPIP promotes epithelial-mesenchymal transition and cisplatin resistance in ovarian cancer cells through PI3K/AKT pathway activation
    Suresh Bugide
    Vijay Kumar Gonugunta
    Vasudevarao Penugurti
    Vijaya Lakshmi Malisetty
    Ratna K. Vadlamudi
    Bramanandam Manavathi
    Cellular Oncology, 2017, 40 : 133 - 144
  • [22] miR-300 regulates the epithelial-mesenchymal transition and invasion of hepatocellular carcinoma by targeting the FAK/PI3K/AKT signaling pathway
    Wang, Rongchang
    Yu, Zheng
    Chen, Fan
    Xu, Hongxu
    Shen, Shunli
    Chen, Wei
    Chen, Lianzhou
    Su, Qiao
    Zhang, Longjuan
    Bi, Jiong
    Zeng, Wentao
    Li, Wen
    Huang, Xiaohui
    Wang, Qian
    BIOMEDICINE & PHARMACOTHERAPY, 2018, 103 : 1632 - 1642
  • [23] TGF-β2 induces epithelial-mesenchymal transition in cultured human lens epithelial cells through activation of the PI3K/Akt/mTOR signaling pathway
    Guo, Rui
    Meng, Qianli
    Guo, Haike
    Xiao, Lijia
    Yang, Xiaohong
    Cui, Ying
    Huang, Yu
    MOLECULAR MEDICINE REPORTS, 2016, 13 (02) : 1105 - 1110
  • [24] Dedicator of cytokinesis protein 2 activates the epithelial-mesenchymal transition in renal fibrosis through the Rac1/PI3K/AKT pathway
    Jia, Yuanyuan
    Sun, Jing
    Chen, Sha
    Bian, Yu
    Jiang, Anni
    Liang, Haihai
    Du, Xuanyi
    BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH, 2025, 1872 (02):
  • [25] TGFBI promotes proliferation and epithelial-mesenchymal transition in renal cell carcinoma through PI3K/AKT/mTOR/HIF-1α pathway
    Zhan, Shanzhi
    Bai, Xiaojie
    Zhao, Yiqiao
    Tuoheti, Kuerban
    Yisha, Zuhaer
    Zuo, Yingtong
    Lu, Peixiang
    Liu, Tongzu
    CANCER CELL INTERNATIONAL, 2024, 24 (01)
  • [26] α-Mangostin Suppresses the Viability and Epithelial-Mesenchymal Transition of Pancreatic Cancer Cells by Downregulating the PI3K/Akt Pathway
    Xu, Qinhong
    Ma, Jiguang
    Lei, Jianjun
    Duan, Wanxing
    Sheng, Liang
    Chen, Xin
    Hu, Ang
    Wang, Zheng
    Wu, Zheng
    Wu, Erxi
    Ma, Qingyong
    Li, Xuqi
    BIOMED RESEARCH INTERNATIONAL, 2014, 2014
  • [27] FAM83A signaling induces epithelial-mesenchymal transition by the PI3K/AKT/Snail pathway in NSCLC
    Zhou, Fengrui
    Geng, Jianxiong
    Xu, Shanqi
    Meng, Qingwei
    Chen, Kexin
    Liu, Fang
    Yang, Fang
    Pan, Bo
    Yu, Yan
    AGING-US, 2019, 11 (16): : 6069 - 6088
  • [28] MicroRNA-1296 inhibits metastasis and epithelial-mesenchymal transition of hepatocellular carcinoma by targeting SRPK1-mediated PI3K/AKT pathway
    Xu, Qiuran
    Liu, Xin
    Liu, Zhikui
    Zhou, Zhenyu
    Wang, Yufeng
    Tu, Jianfeng
    Li, Lijie
    Bao, Hangxing
    Yang, Liu
    Tu, Kangsheng
    MOLECULAR CANCER, 2017, 16
  • [29] MicroRNA-1296 inhibits metastasis and epithelial-mesenchymal transition of hepatocellular carcinoma by targeting SRPK1-mediated PI3K/AKT pathway
    Qiuran Xu
    Xin Liu
    Zhikui Liu
    Zhenyu Zhou
    Yufeng Wang
    Jianfeng Tu
    Lijie Li
    Hangxing Bao
    Liu Yang
    Kangsheng Tu
    Molecular Cancer, 16
  • [30] ING5 inhibits epithelial-mesenchymal transition in breast cancer by suppressing PI3K/Akt pathway
    Zhao, Qing-Ye
    Ju, Fang
    Wang, Zhi-Hai
    Ma, Xue-Zhen
    Zhao, Hui
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2015, 8 (09): : 15498 - 15505